Who
Mark T. Iwicki
Director
Company insider
Files Form 4 as: Director, Q32 Bio; Chief Executive Officer, Inhibikase Therapeutics; Director, Merus; Director, Akero Therapeutics; Chief Executive Officer, Kala Bio; Director, Third Harmonic Bio; Director, Jade Biosciences; Director, Pulmatrix.
In numbers
- Trades disclosed
- 151
- Buys
- 3
- Sells
- 14
- Bought
- $620K
- Sold
- $570K
- Companies
- 10
- Companies where not an officer
- 7
- First trade
- 18 Oct 2007
- Last trade
- 12 Jun 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,982,706 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,982,706 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —13,193 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,844 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —14,414 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —16,604 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —6,120 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,631 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —5,650 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —4,983 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,500 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merus | SEC FORM 4 Code U | $7.1M73,576 at $97.00 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,000 | filing |
News
No headline names them, or the companies they trade most, lately.